INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes (INSPIRE)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Intensive insulin
Routine Care
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring diabetes, insulin, rescue therapy
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed T2DM (≤ 6 months since diagnosis)
- Drug naïve (less than 2 weeks of insulin and OHAs)
- A1C ≥ 8%
- Age ≥ 18 years
- Normal to high baseline C-peptide (≥ 0.5 ug/dL)
- FBG > 180 mg/dL, A1C > 8%.
Exclusion Criteria:
- Pregnancy
- Clinically evident heart failure
- Nephrotic syndrome
- Allergy to insulin or any of the oral medications in the study
- Presence of anti-GAD antibodies
- Islet cell antibodies
- Anti-insulin antibodies
- Any physical disabilities that would preclude self-administration of injectable insulin.
- Evidence of hypoglycemia during screening phase.
- History of lactic acidosis, allergy to metformin or history of chronic renal disease or a serum creatinine > 1.5 in men or > 1.4 in women
Sites / Locations
- Ohio University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Intensive insulin regimen
Routine Care
Arm Description
A weight based, basal bolus will be given for 12 weeks.
Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
Outcomes
Primary Outcome Measures
The need for rescue therapy
The need for rescue therapy
The need for rescue therapy
The need for rescue therapy
Secondary Outcome Measures
A1c,C-peptide. Time to normoglycemia and rescue therapy. Mean glucose, mean FBG, HOMA-B, HOMA-IR. Hypoglycemic events (minor and major. Tolerability based on side effects.
Full Information
NCT ID
NCT01087567
First Posted
March 15, 2010
Last Updated
April 16, 2014
Sponsor
Ohio University
Collaborators
Western University of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT01087567
Brief Title
INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes
Acronym
INSPIRE
Official Title
A Pilot Study of Intensive Insulin Regimen as a Primary Treatment of New Onset of Type 2 DM
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
July 2010 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ohio University
Collaborators
Western University of Health Sciences
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
T2DM has become an American Epidemic. Currently 8% of the US population has diabetes and rates may be as high as 33% by the year 2050 (1). Although there are many treatment options for people with T2DM, none have been proven in humans to prevent the defects in insulin secretion (2) and insulin action (3) and beta cell dysfunction (4) that result with very high glucose levels and typically worsen as the disease progresses. Any treatment that could delay the progression of pancreatic beta cell failure (as measured by the need for rescue therapy with oral agents) would be a significant advancement in diabetes treatment.
Insulin therapy is appropriate at any point in T2DM disease progression, but it is commonly only used as a rescue therapy after failure of oral therapies. A number of outpatient insulin titration protocols have been shown to be safe and effective and speed patient's ability to gain glucose control (5-8). Recent studies have shown that initiation of insulin at onset of T2DM is beneficial at achieving early and long-term glucose control (6-9). However these protocols have used intravenous human insulin in the in-patient setting, continuous subcutaneous insulin by insulin pump or older human insulins in the out-patient setting. Many of these protocols are unlikely to be utilized in routine patient care. To date, no "insulin first" studies have been published with analog insulins in an outpatient basal-bolus regimen with patient driven titration.
Detailed Description
Insulin, when used as an initial treatment of T2DM, has a great potential to produce glucose control faster than any other treatment regimen. However, it is typically used as the treatment of last resort in T2DM. In this study, the investigators offer a novel approach to use insulin as the initial therapy in new-onset T2DM with the aim of determining its efficacy toward producing lasting glucose control.
Hypothesis: Treating newly diagnosed T2DM patients with insulin therapy versus standard of care for a short period of time will lead to improvement in glycemic control that is durable beyond the length of time taking the insulin and it may improve beta cell function.
Primary endpoints: Time to need rescue therapy, Need for rescue therapy at all time points. A1C change at 3, 6, 9 and 12 months.
Secondary endpoints: Mean glucose and mean fasting glucose at 3, 6, 12 months. C-peptide, HOMA-B, HOMA-IR, A1C the same time points, OGTT at week 12 and 56. Total number of hypoglycemic events (minor and major) and tolerability based on side effects.
Treatment arm: Weight based protocol of insulin Glargine and Glulisine. Control arm: oral medications per ADA 2009 recommended treatment algorithm. Rescue group available for both arms after initial 12 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
diabetes, insulin, rescue therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
23 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intensive insulin regimen
Arm Type
Experimental
Arm Description
A weight based, basal bolus will be given for 12 weeks.
Arm Title
Routine Care
Arm Type
Active Comparator
Arm Description
Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
Intervention Type
Drug
Intervention Name(s)
Intensive insulin
Other Intervention Name(s)
Lantus Insulin, Apidra Insulin
Intervention Description
A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
Intervention Type
Drug
Intervention Name(s)
Routine Care
Other Intervention Name(s)
Metformin, Glimepiride, Pioglitazone
Intervention Description
Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
Primary Outcome Measure Information:
Title
The need for rescue therapy
Time Frame
at 3 months
Title
The need for rescue therapy
Time Frame
at 6 months
Title
The need for rescue therapy
Time Frame
at 9 months
Title
The need for rescue therapy
Time Frame
at 12 months
Secondary Outcome Measure Information:
Title
A1c,C-peptide. Time to normoglycemia and rescue therapy. Mean glucose, mean FBG, HOMA-B, HOMA-IR. Hypoglycemic events (minor and major. Tolerability based on side effects.
Time Frame
3 months, 6 months, 9 months, 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed T2DM (≤ 6 months since diagnosis)
Drug naïve (less than 2 weeks of insulin and OHAs)
A1C ≥ 8%
Age ≥ 18 years
Normal to high baseline C-peptide (≥ 0.5 ug/dL)
FBG > 180 mg/dL, A1C > 8%.
Exclusion Criteria:
Pregnancy
Clinically evident heart failure
Nephrotic syndrome
Allergy to insulin or any of the oral medications in the study
Presence of anti-GAD antibodies
Islet cell antibodies
Anti-insulin antibodies
Any physical disabilities that would preclude self-administration of injectable insulin.
Evidence of hypoglycemia during screening phase.
History of lactic acidosis, allergy to metformin or history of chronic renal disease or a serum creatinine > 1.5 in men or > 1.4 in women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jay H Shubrook, D.O.
Organizational Affiliation
Ohio University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ohio University
City
Athens
State/Province
Ohio
ZIP/Postal Code
45701
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
15111515
Citation
Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004 May;27(5):1028-32. doi: 10.2337/diacare.27.5.1028.
Results Reference
background
PubMed Identifier
18502299
Citation
Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008 May 24;371(9626):1753-60. doi: 10.1016/S0140-6736(08)60762-X.
Results Reference
background
PubMed Identifier
18556343
Citation
Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008 Oct;31(10):1927-32. doi: 10.2337/dc08-0075. Epub 2008 Jun 12.
Results Reference
background
Learn more about this trial
INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes
We'll reach out to this number within 24 hrs